PMID- 8883970
OWN - NLM
STAT- MEDLINE
DCOM- 19970515
LR  - 20190905
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 40
IP  - 3
DP  - 1996
TI  - Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined 
      by differentially competitive polymerase chain reaction.
PG  - 271-81
AB  - A new method of measuring gene copy number in small samples of DNA was used to 
      measure amplification of the erbB-2 gene and of chromosome 20q in breast cancer. 
      This method, termed 'differentially competitive polymerase chain reaction' 
      (DC-PCR) combines the advantages of two other techniques for measuring 
      amplification by PCR, namely differential PCR and competitive PCR. The DC-PCR 
      methodology was evaluated for sensitivity and specificity by comparing 
      amplification of erbB-2 measured by DC-PCR with that obtained by fluorescence in 
      situ hybridization (FISH) for 42 cases or Southern blotting and/or slot blot 
      analysis for 34 cases. There was over 90 percent concordance with both FISH and 
      Southern blotting and/or slot blot analysis. DC-PCR was used to further 
      characterize the newly described amplicon at chromosome 20q. By analyzing DNA 
      from 10 breast cancer cell lines at 7 different loci, we identified a potential 
      common region of amplification of approximately 5 centimorgans at chromosome 
      20q13 bordered by loci D20S52 and RMC20C100-S1. One hundred and seventeen cases 
      of primary breast cancer were evaluated for amplification at these two loci. 
      Amplification at one or more loci, defined as > 1.5 fold higher copy number than 
      that of normal DNA, was found in 25 cases (21%). Sixteen cases were amplified at 
      only one of the two probes (12 cases for RMC20C001-S1 and 4 cases for D20S52), 
      suggesting that the target gene lies between the two markers or that there are 
      two independent target genes within a small chromosome region.
FAU - Deng, G
AU  - Deng G
AD  - Geraldine Brush Cancer Research Institute at California Pacific Medical Center, 
      San Francisco 94115, USA.
FAU - Yu, M
AU  - Yu M
FAU - Chen, L C
AU  - Chen LC
FAU - Moore, D
AU  - Moore D
FAU - Kurisu, W
AU  - Kurisu W
FAU - Kallioniemi, A
AU  - Kallioniemi A
FAU - Waldman, F M
AU  - Waldman FM
FAU - Collins, C
AU  - Collins C
FAU - Smith, H S
AU  - Smith HS
LA  - eng
GR  - 1 P01 CA44768/CA/NCI NIH HHS/United States
GR  - 1 P01 CA58207/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Blotting, Southern
MH  - Breast Neoplasms/*genetics
MH  - *Chromosomes, Human, Pair 20
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1007/BF01806816 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 1996;40(3):271-81. doi: 10.1007/BF01806816.